Educational content only. Not medical advice. Consult a qualified physician.
Semax peptide
CognitiveApproved in Russia and Ukraine for several neurological indications. Not FDA-approved in the United States.

Semax

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added Pro-Gly-Pro C-terminal tripeptide for metabolic stability. Developed in Russia, it is approved there for conditions including stroke recovery, cognitive disorders, and peptic ulcers. It is administered intranasally.
Reported Benefits

Potential Benefits

  • Approved in Russia for stroke, cognitive disorders, and neurodegenerative conditions
  • Research suggests neuroprotective properties through BDNF upregulation
  • Studies indicate potential improvements in attention, memory, and mental clarity
  • May support recovery from brain injuries based on clinical data from Russian studies
  • Preclinical research suggests anti-inflammatory effects in neural tissue
  • Does not appear to cause significant sedation or stimulation
Research Dosing

Recommended Starting Dose

200-600 mcg intranasally per day

Based on published research protocols. Not a prescription.

Dosing Protocol

Administered intranasally at 200-600 mcg per day, typically divided into 2-3 doses. A standard course in Russian clinical practice is 10-14 days, which may be repeated after a break. Higher doses (up to 1.2 mg/day) are used in some clinical settings for acute neurological conditions.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Cognitive effects such as improved focus and mental clarity are often reported within the first 3-5 days. Neuroprotective benefits in clinical applications require sustained use.

Regulatory

Research Status

Approved in Russia and Ukraine for several neurological indications. Not FDA-approved in the United States.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Nasal dryness or irritation
  • Mild headache in some users
  • Hair loss reported anecdotally at higher doses
  • Potential irritability in sensitive individuals
  • Limited Western clinical safety data
  • Possible interactions with psychoactive medications
Related Research

More in Cognitive

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.